Akoya Gross Profit from 2010 to 2025

AKYA Stock

USD 1.70 0.02 1.19%

Akoya Biosciences' Gross Profit is increasing over the years with slightly volatile fluctuation. Gross Profit is expected to dwindle to about 42.6 M. Gross Profit is the profit Akoya Biosciences makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2020-03-31

Previous Quarter

11.7 M

Current Value

14.4 M

Quarterly Volatility

3 M

Covid

Check Akoya Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akoya Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 73.5 K, Depreciation And Amortization of 6.4 M or Interest Expense of 5.8 M, as well as many indicators such as Price To Sales Ratio of 1.32, Dividend Yield of 0.002 or PTB Ratio of 15.65. Akoya financial statements analysis is a perfect complement when working with Akoya Biosciences Valuation or Volatility modules.

Check out the analysis of Akoya Biosciences Correlation against competitors.

For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.

Latest Akoya Biosciences' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Akoya Biosciences over the last few years. Gross profit is a required income statement account that reflects total revenue of Akoya Biosciences minus its cost of goods sold. It is profit before Akoya Biosciences operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Akoya Biosciences' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akoya Biosciences' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 47.88 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Akoya Gross Profit Regression Statistics

	Arithmetic Mean	31,058,044
	Geometric Mean	29,706,512
	Coefficient Of Variation	33.78
	Mean Deviation	8,637,560
	Median	24,663,000
	Standard Deviation	10,491,523
	Sample Variance	110.1T
	Range	31.6M
	R-Value	0.77
	Mean Square Error	47.2T
	R-Squared	0.60
	Significance	0.0004
	Slope	1,706,707
	Total Sum of Squares	1651.1T

Akoya Gross Profit History

	2025	42.6 M
	2024	47.9 M
	2023	56.3 M
	2022	43.4 M
	2021	34.2 M
	2020	25.9 M

Other Fundumenentals of Akoya Biosciences

Gross Profit Margin

Akoya Biosciences Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Deferred Long Term Liab	Short Long Term Debt	Long Term Debt Total	Capital Surpluse
Total Assets		0.89	0.95	0.73	-0.71	-0.72	0.8	0.72	-0.02	-0.3	-0.14	-0.16	0.85	1.0	-0.78	0.99	0.68	-0.7	0.75	0.78	-0.95	-0.3	0.65	0.38
Total Stockholder Equity	0.89		0.86	0.45	-0.82	-0.51	0.81	0.55	-0.38	-0.08	-0.42	-0.56	0.64	0.9	-0.83	0.92	0.53	-0.53	0.79	0.65	-0.86	-0.08	0.44	0.2
Net Tangible Assets	0.95	0.86		0.72	-0.8	-0.78	0.83	0.72	-0.04	-0.44	0.05	-0.22	0.79	0.97	-0.8	0.96	0.6	-0.78	0.8	0.81	-0.99	-0.44	0.67	0.56
Current Deferred Revenue	0.73	0.45	0.72		-0.17	-0.92	0.24	0.96	0.34	-0.51	0.31	0.29	0.96	0.7	-0.68	0.64	0.84	-0.89	0.71	0.93	-0.78	-0.51	0.98	0.76
Net Debt	-0.71	-0.82	-0.8	-0.17		0.29	-0.97	-0.2	0.27	0.12	0.21	0.52	-0.3	-0.76	0.51	-0.81	-0.1	0.34	-0.5	-0.37	0.73	0.12	-0.12	-0.14
Retained Earnings	-0.72	-0.51	-0.78	-0.92	0.29		-0.33	-0.95	-0.16	0.73	-0.4	-0.03	-0.87	-0.7	0.81	-0.66	-0.74	0.99	-0.85	-0.91	0.83	0.73	-0.92	-0.88
Accounts Payable	0.8	0.81	0.83	0.24	-0.97	-0.33		0.23	-0.13	-0.15	-0.21	-0.36	0.38	0.83	-0.48	0.88	0.15	-0.35	0.45	0.37	-0.75	-0.15	0.15	0.09
Long Term Debt	0.72	0.55	0.72	0.96	-0.2	-0.95	0.23		0.16	-0.5	0.21	0.06	0.94	0.69	-0.82	0.64	0.85	-0.94	0.85	0.97	-0.81	-0.5	0.98	0.78
Net Receivables	-0.02	-0.38	-0.04	0.34	0.27	-0.16	-0.13	0.16		-0.09	0.32	0.84	0.18	-0.02	0.36	-0.05	-0.12	-0.12	-0.31	0.08	0.06	-0.09	0.21	0.17
Good Will	-0.3	-0.08	-0.44	-0.51	0.12	0.73	-0.15	-0.5	-0.09		-0.78	-0.03	-0.36	-0.28	0.46	-0.26	-0.33	0.73	-0.5	-0.42	0.45	1.0	-0.5	-0.81
Short Term Investments	-0.14	-0.42	0.05	0.31	0.21	-0.4	-0.21	0.21	0.32	-0.78		0.44	0.06	-0.15	0.07	-0.19	0.09	-0.39	0.02	0.16	-0.05	-0.78	0.32	0.71
Total Liab	-0.16	-0.56	-0.22	0.29	0.52	-0.03	-0.36	0.06	0.84	-0.03	0.44		0.13	-0.19	0.51	-0.25	0.05	0.05	-0.47	-0.01	0.22	-0.03	0.2	0.1
Net Invested Capital	0.85	0.64	0.79	0.96	-0.3	-0.87	0.38	0.94	0.18	-0.36	0.06	0.13		0.82	-0.76	0.77	0.89	-0.83	0.77	0.94	-0.85	-0.36	0.93	0.6
Total Current Assets	1.0	0.9	0.97	0.7	-0.76	-0.7	0.83	0.69	-0.02	-0.28	-0.15	-0.19	0.82		-0.77	1.0	0.63	-0.69	0.74	0.77	-0.96	-0.28	0.62	0.38
Capital Stock	-0.78	-0.83	-0.8	-0.68	0.51	0.81	-0.48	-0.82	0.36	0.46	0.07	0.51	-0.76	-0.77		-0.76	-0.73	0.83	-0.99	-0.82	0.86	0.46	-0.72	-0.59
Net Working Capital	0.99	0.92	0.96	0.64	-0.81	-0.66	0.88	0.64	-0.05	-0.26	-0.19	-0.25	0.77	1.0	-0.76		0.57	-0.66	0.73	0.72	-0.95	-0.26	0.56	0.33
Short Term Debt	0.68	0.53	0.6	0.84	-0.1	-0.74	0.15	0.85	-0.12	-0.33	0.09	0.05	0.89	0.63	-0.73	0.57		-0.7	0.73	0.84	-0.69	-0.33	0.87	0.54
Intangible Assets	-0.7	-0.53	-0.78	-0.89	0.34	0.99	-0.35	-0.94	-0.12	0.73	-0.39	0.05	-0.83	-0.69	0.83	-0.66	-0.7		-0.87	-0.91	0.84	0.73	-0.9	-0.9
Common Stock	0.75	0.79	0.8	0.71	-0.5	-0.85	0.45	0.85	-0.31	-0.5	0.02	-0.47	0.77	0.74	-0.99	0.73	0.73	-0.87		0.86	-0.86	-0.5	0.77	0.67
Property Plant Equipment	0.78	0.65	0.81	0.93	-0.37	-0.91	0.37	0.97	0.08	-0.42	0.16	-0.01	0.94	0.77	-0.82	0.72	0.84	-0.91	0.86		-0.88	-0.42	0.96	0.76
Deferred Long Term Liab	-0.95	-0.86	-0.99	-0.78	0.73	0.83	-0.75	-0.81	0.06	0.45	-0.05	0.22	-0.85	-0.96	0.86	-0.95	-0.69	0.84	-0.86	-0.88		0.45	-0.75	-0.61
Short Long Term Debt	-0.3	-0.08	-0.44	-0.51	0.12	0.73	-0.15	-0.5	-0.09	1.0	-0.78	-0.03	-0.36	-0.28	0.46	-0.26	-0.33	0.73	-0.5	-0.42	0.45		-0.5	-0.81
Long Term Debt Total	0.65	0.44	0.67	0.98	-0.12	-0.92	0.15	0.98	0.21	-0.5	0.32	0.2	0.93	0.62	-0.72	0.56	0.87	-0.9	0.77	0.96	-0.75	-0.5		0.82
Capital Surpluse	0.38	0.2	0.56	0.76	-0.14	-0.88	0.09	0.78	0.17	-0.81	0.71	0.1	0.6	0.38	-0.59	0.33	0.54	-0.9	0.67	0.76	-0.61	-0.81	0.82

Click cells to compare fundamentals

About Akoya Biosciences Financial Statements

Akoya Biosciences stakeholders use historical fundamental indicators, such as Akoya Biosciences' Gross Profit, to determine how well the company is positioned to perform in the future. Although Akoya Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Akoya Biosciences' assets and liabilities are reflected in the revenues and expenses on Akoya Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Akoya Biosciences. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	47.9 M	42.6 M
Gross Profit Margin	0.59	0.65

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock:

How To Invest In Akoya

Details

Is Akoya Stock a good investment?

Details

What is Akoya Biosciences' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of Akoya Biosciences Correlation against competitors.

For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.12)

Revenue Per Share

1.653

Quarterly Revenue Growth

(0.19)

Return On Assets

(0.17)

Return On Equity

(1.80)

The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Akoya Gross Profit from 2010 to 2025

Latest Akoya Biosciences' Gross Profit Growth Pattern

Akoya Gross Profit Regression Statistics

Akoya Gross Profit History

Other Fundumenentals of Akoya Biosciences

Akoya Biosciences Gross Profit component correlations

About Akoya Biosciences Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY